|
Volumn 2, Issue 4, 2006, Pages 391-393
|
Cyclosporin-A in the treatment of nephrotic syndrome: The importance of monitoring C0 (Trough) and C2 (two hours after its administration) blood levels
|
Author keywords
C2 blood levels; Cyclosporine; Glomerulonephritis; Nephrotic syndrome
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CREATININE;
CYCLOSPORIN A;
DIURETIC AGENT;
IMMUNOGLOBULIN A;
PREDNISOLONE;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
CREATININE CLEARANCE;
CUSHINGOID SYNDROME;
DISEASE ASSOCIATION;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG MONITORING;
FEMALE;
FOCAL GLOMERULOSCLEROSIS;
HIRSUTISM;
HUMAN;
HYPERTENSION;
IMMUNOGLOBULIN A NEPHROPATHY;
KIDNEY FUNCTION;
LUPUS ERYTHEMATOSUS NEPHRITIS;
MALE;
MEMBRANOUS GLOMERULONEPHRITIS;
MINIMAL CHANGE GLOMERULONEPHRITIS;
NEPHROTIC SYNDROME;
PRIORITY JOURNAL;
RELAPSE;
REMISSION;
TIME;
TREATMENT DURATION;
CYCLOSPORINE;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
METABOLIC DETOXICATION, DRUG;
MIDDLE AGED;
MONITORING, PHYSIOLOGIC;
NEPHROTIC SYNDROME;
RECURRENCE;
REMISSION INDUCTION;
|
EID: 33746153158
PISSN: 15734064
EISSN: None
Source Type: Journal
DOI: 10.2174/157340606777724068 Document Type: Article |
Times cited : (6)
|
References (9)
|